Literature DB >> 19229116

Serum phosphate and left ventricular hypertrophy in young adults: the coronary artery risk development in young adults study.

Robert N Foley1, Allan J Collins, Charles A Herzog, Areef Ishani, Philip A Kalra.   

Abstract

BACKGROUND/AIMS: A relationship with vascular dysfunction in chronic kidney disease suggests a possible association of phosphate level with left ventricular hypertrophy development in people with normal kidney function. We aimed to determine whether such an association exists in community-dwelling young adults.
METHODS: This is a cohort study of participants in the ongoing, community-based, prospective Coronary Artery Risk Development in Young Adults study (n = 4,055). Phosphate levels were measured at year 0, and left ventricular hypertrophy assessed by echocardiography at year 5.
RESULTS: The mean age was 25.0 years. Mean values were: estimated glomerular filtration rate 118.5 ml/min/1.73 m(2); phosphate 3.7 mg/dl; left ventricular mass indexed to body surface area 80.5 g/m(2), and indexed to height(2.7) 35.2 g/m(2.7). Left ventricular hypertrophy was present in 4.5% of the population. As a continuous variable, the phosphate level was associated with left ventricular hypertrophy (odds ratio per standard deviation 1.27; 95% confidence interval 1.09-1.47; p = 0.0020). This association persisted after covariate adjustment (odds ratio per standard deviation 1.30; 95% confidence interval 1.10-1.54; p = 0.0018), and was most pronounced for fifth quintile phosphate levels (>4.0 mg/dl).
CONCLUSION: Phosphate level may be a risk factor for left ventricular hypertrophy in community-dwelling young adults. As phosphate levels may be modifiable, the causality of this association can be addressed with controlled trials. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19229116     DOI: 10.1159/000203348

Source DB:  PubMed          Journal:  Kidney Blood Press Res        ISSN: 1420-4096            Impact factor:   2.687


  19 in total

Review 1.  Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease.

Authors:  Julia J Scialla; Myles Wolf
Journal:  Nat Rev Nephrol       Date:  2014-04-01       Impact factor: 28.314

2.  Ferric citrate (auryxia) for the treatment of hyperphosphatemia.

Authors:  Adam Pennoyer; Mary Barna Bridgeman
Journal:  P T       Date:  2015-05

3.  Relations of serum phosphorus levels to echocardiographic left ventricular mass and incidence of heart failure in the community.

Authors:  Ravi Dhingra; Philimon Gona; Emelia J Benjamin; Thomas J Wang; Jayashri Aragam; Ralph B D'Agostino; William B Kannel; Ramachandran S Vasan
Journal:  Eur J Heart Fail       Date:  2010-08       Impact factor: 15.534

Review 4.  Arterial calcification and bone physiology: role of the bone-vascular axis.

Authors:  Bithika Thompson; Dwight A Towler
Journal:  Nat Rev Endocrinol       Date:  2012-04-03       Impact factor: 43.330

Review 5.  Klotho, the Holy Grail of the kidney: from salt sensitivity to chronic kidney disease.

Authors:  Rigas G Kalaitzidis; Anila Duni; Kostas C Siamopoulos
Journal:  Int Urol Nephrol       Date:  2016-05-23       Impact factor: 2.370

6.  A Controlled Increase in Dietary Phosphate Elevates BP in Healthy Human Subjects.

Authors:  Jaber Mohammad; Roberto Scanni; Lukas Bestmann; Henry N Hulter; Reto Krapf
Journal:  J Am Soc Nephrol       Date:  2018-07-18       Impact factor: 10.121

Review 7.  Phosphate Is a Cardiovascular Toxin.

Authors:  Maren Leifheit-Nestler; Isabel Vogt; Dieter Haffner; Beatrice Richter
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

8.  Cardiovascular effects of sevelamer in stage 3 CKD.

Authors:  Colin D Chue; Jonathan N Townend; William E Moody; Daniel Zehnder; Nadezhda A Wall; Lorraine Harper; Nicola C Edwards; Richard P Steeds; Charles J Ferro
Journal:  J Am Soc Nephrol       Date:  2013-04-18       Impact factor: 10.121

9.  Serum magnesium, phosphorus, and calcium are associated with risk of incident heart failure: the Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  Pamela L Lutsey; Alvaro Alonso; Erin D Michos; Laura R Loehr; Brad C Astor; Josef Coresh; Aaron R Folsom
Journal:  Am J Clin Nutr       Date:  2014-07-16       Impact factor: 7.045

Review 10.  Phosphate: an old bone molecule but new cardiovascular risk factor.

Authors:  Navid Shobeiri; Michael A Adams; Rachel M Holden
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.